Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

BACKGROUND: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. METHODS: We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be able to reverse the anticoagulant effect of dabigatran in patients who had uncontrolled bleeding (group A) or were about to undergo an urgent procedure (group B). The primary end point was the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of idarucizumab, on the basis of the diluted thrombin time or ecarin clotting time. Secondary end points included the restoration of hemostasis and safety measures. RESULTS: A total of 503 patients were enrolled: 301 in group A, and 202 in group B. The median maximum percentage reversal of dabigatran was 100% (95% confidence interval, 100 to 100), on the basis of either the diluted thrombin time or the ecarin clotting time. In group A, 137 patients (45.5%) presented with gastrointestinal bleeding and 98 (32.6%) presented with intracranial hemorrhage; among the patients who could be assessed, the median time to the cessation of bleeding was 2.5 hours. In group B, the median time to the initiation of the intended procedure was 1.6 hours; periprocedural hemostasis was assessed as normal in 93.4% of the patients, mildly abnormal in 5.1%, and moderately abnormal in 1.5%. At 90 days, thrombotic events had occurred in 6.3% of the patients in group A and in 7.4% in group B, and the mortality rate was 18.8% and 18.9%, respectively. There were no serious adverse safety signals. CONCLUSIONS: In emergency situations, idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran. (Funded by Boehringer Ingelheim; RE-VERSE AD number, NCT02104947 .).

Full Text

Duke Authors

Cited Authors

  • Pollack, CV; Reilly, PA; van Ryn, J; Eikelboom, JW; Glund, S; Bernstein, RA; Dubiel, R; Huisman, MV; Hylek, EM; Kam, C-W; Kamphuisen, PW; Kreuzer, J; Levy, JH; Royle, G; Sellke, FW; Stangier, J; Steiner, T; Verhamme, P; Wang, B; Young, L; Weitz, JI

Published Date

  • August 3, 2017

Published In

Volume / Issue

  • 377 / 5

Start / End Page

  • 431 - 441

PubMed ID

  • 28693366

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1707278


  • eng

Conference Location

  • United States